Gonadorelin
- Generic Name
- Gonadorelin
- Brand Names
- Lutrepulse
- Drug Type
- Small Molecule
- Chemical Formula
- C55H75N17O13
- CAS Number
- 33515-09-2
- Unique Ingredient Identifier
- 9O7312W37G
- Background
Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
- Indication
For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
- Associated Therapies
- Ovulation induction therapy
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
- Conditions
- EndometriosisDysmenorrheaDyspareunia
- Interventions
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 112
- Registration Number
- NCT00458458
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH
- Conditions
- Premature Ovarian FailureInfertility
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Eugonia
- Target Recruit Count
- 135
- Registration Number
- NCT00417157
- Locations
- 🇬🇷
Eugonia, Athens, Greece
The Effects of Aging and Estrogen on the Pituitary
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT00386022
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Pulsatile GnRH in Anovulatory Infertility
- Conditions
- Kallmann's SyndromeHypogonadotropic HypogonadismAmenorrhea
- Interventions
- Device: Pump
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT00383656
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Letrozole Treatment in Normal and GnRH Deficient Women
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00351416
- Locations
- 🇺🇸
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, United States
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00099086
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
- Conditions
- Metastatic CancerProstate Cancer
- Interventions
- Other: placeboDrug: androgen deprivation therapyDietary Supplement: Calcium supplementDietary Supplement: Vitamin D
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 645
- Registration Number
- NCT00079001
- Locations
- 🇺🇸
Good Samaritan Hospital of Maryland, Baltimore, Maryland, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Fisher-Titus Medical Center, Norwalk, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.